Nanotherapeutic strategy against glioblastoma using enzyme inhibitors

Glioblastoma is the most aggressive brain cancer and thus patients with glioblastoma have a severely low 5-year survival rate (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2024-12, Vol.181, p.117713, Article 117713
Hauptverfasser:	Thiruvengadam, Rekha, Dareowolabi, Boluwatife Olamide, Moon, Eun-Yi, Kim, Jin Hee
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - mortality Enzyme inhibitor Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Glioblastoma Glioblastoma - drug therapy Glioblastoma - mortality Humans Nanomedicine - methods Nanoparticles Nanotherapeutics Neuroinflammation Tumor Microenvironment - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Glioblastoma is the most aggressive brain cancer and thus patients with glioblastoma have a severely low 5-year survival rate (
ISSN:	0753-3322 1950-6007 1950-6007
DOI:	10.1016/j.biopha.2024.117713